Form 4: Bio-Rad Laboratories CEO Norman Schwartz Reports Stock Option Grant and Beneficial Ownership Changes

Norman Schwartz, CEO of Bio-Rad Laboratories, reports the acquisition of stock options and changes in beneficial ownership of Bio-Rad common stock.

Summary

• Norman Schwartz, the Chairman, President, and CEO of Bio-Rad Laboratories, filed a Form 4 with the SEC.
• The filing reports the acquisition of 14,137 non-qualified stock options with an exercise price of $343.76 on March 8, 2024.
• These options vest over four years, at a rate of 25% per year on the anniversary of the grant date, and expire on March 8, 2034.
• The filing also details Mr. Schwartz's direct and indirect beneficial ownership of Bio-Rad A and B Common Stock.
• Mr. Schwartz directly owns 432,920 shares of Bio-Rad A Common Stock and 361,409 shares of Bio-Rad B Common Stock.
• He also indirectly owns 12,949 shares of Bio-Rad B Common Stock through his spouse and 4,060,054 shares through Blue Raven Partners, L.P., where he is a limited and general partner.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions and holdings.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve company performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing is typical for executives receiving stock options as part of their compensation.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with their own.

Key Dates